11.52 USD
+0.3 (+2.67%)
11.583 USD
+0.06 (+0.55%)
Taking everything into account, XRAY scores 4 out of 10 in our fundamental rating. XRAY was compared to 185 industry peers in the Health Care Equipment & Supplies industry. XRAY has a medium profitability rating, but doesn't score so well on its financial health evaluation. XRAY is valued quite cheap, but it does not seem to be growing. Finally XRAY also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
In the past year XRAY was profitable.
XRAY had a positive operating cash flow in the past year.
In the past 5 years XRAY reported 4 times negative net income.
XRAY had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -15.60%, XRAY is in line with its industry, outperforming 56.76% of the companies in the same industry.
XRAY has a Return On Equity (-59.68%) which is in line with its industry peers.
XRAY has a Return On Invested Capital of 5.04%. This is in the better half of the industry: XRAY outperforms 76.22% of its industry peers.
The Average Return On Invested Capital over the past 3 years for XRAY is below the industry average of 8.82%.
The last Return On Invested Capital (5.04%) for XRAY is above the 3 year average (4.11%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.6% | ||
| ROE | -59.68% | ||
| ROIC | 5.04% |
ROA(3y)-10.01%
ROA(5y)-5.27%
ROE(3y)-25.27%
ROE(5y)-13.81%
ROIC(3y)4.11%
ROIC(5y)4.26%
1.3 Margins
XRAY's Operating Margin of 7.48% is fine compared to the rest of the industry. XRAY outperforms 74.05% of its industry peers.
In the last couple of years the Operating Margin of XRAY has declined.
XRAY has a Gross Margin (51.10%) which is in line with its industry peers.
In the last couple of years the Gross Margin of XRAY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.48% | ||
| PM (TTM) | N/A | ||
| GM | 51.1% |
OM growth 3Y-25.8%
OM growth 5Y-12.74%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.16%
GM growth 5Y-0.95%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so XRAY is destroying value.
The number of shares outstanding for XRAY has been reduced compared to 1 year ago.
Compared to 5 years ago, XRAY has less shares outstanding
Compared to 1 year ago, XRAY has a worse debt to assets ratio.
2.2 Solvency
XRAY has an Altman-Z score of 0.92. This is a bad value and indicates that XRAY is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.92, XRAY is in line with its industry, outperforming 49.73% of the companies in the same industry.
The Debt to FCF ratio of XRAY is 29.94, which is on the high side as it means it would take XRAY, 29.94 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of XRAY (29.94) is better than 68.65% of its industry peers.
A Debt/Equity ratio of 1.36 is on the high side and indicates that XRAY has dependencies on debt financing.
The Debt to Equity ratio of XRAY (1.36) is worse than 78.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.36 | ||
| Debt/FCF | 29.94 | ||
| Altman-Z | 0.92 |
ROIC/WACC0.81
WACC6.19%
2.3 Liquidity
A Current Ratio of 1.47 indicates that XRAY should not have too much problems paying its short term obligations.
XRAY has a Current ratio of 1.47. This is in the lower half of the industry: XRAY underperforms 76.76% of its industry peers.
A Quick Ratio of 0.99 indicates that XRAY may have some problems paying its short term obligations.
XRAY has a worse Quick ratio (0.99) than 76.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.47 | ||
| Quick Ratio | 0.99 |
3. Growth
3.1 Past
The earnings per share for XRAY have decreased strongly by -14.59% in the last year.
XRAY shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -7.38% yearly.
XRAY shows a decrease in Revenue. In the last year, the revenue decreased by -7.08%.
Measured over the past years, XRAY shows a decrease in Revenue. The Revenue has been decreasing by -1.17% on average per year.
EPS 1Y (TTM)-14.59%
EPS 3Y-16.51%
EPS 5Y-7.38%
EPS Q2Q%-26%
Revenue 1Y (TTM)-7.08%
Revenue growth 3Y-3.58%
Revenue growth 5Y-1.17%
Sales Q2Q%-4.94%
3.2 Future
The Earnings Per Share is expected to grow by 7.40% on average over the next years.
The Revenue is expected to grow by 1.34% on average over the next years.
EPS Next Y-1.97%
EPS Next 2Y-1.68%
EPS Next 3Y2.65%
EPS Next 5Y7.4%
Revenue Next Year-4.33%
Revenue Next 2Y-1.81%
Revenue Next 3Y-0.41%
Revenue Next 5Y1.34%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 7.29, the valuation of XRAY can be described as very cheap.
Based on the Price/Earnings ratio, XRAY is valued cheaply inside the industry as 97.30% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of XRAY to the average of the S&P500 Index (26.57), we can say XRAY is valued rather cheaply.
With a Price/Forward Earnings ratio of 7.14, the valuation of XRAY can be described as very cheap.
Based on the Price/Forward Earnings ratio, XRAY is valued cheaply inside the industry as 98.92% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 24.04, XRAY is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.29 | ||
| Fwd PE | 7.14 |
4.2 Price Multiples
XRAY's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. XRAY is cheaper than 96.22% of the companies in the same industry.
XRAY's Price/Free Cash Flow ratio is rather cheap when compared to the industry. XRAY is cheaper than 81.08% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 28.74 | ||
| EV/EBITDA | 6.91 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.68%
EPS Next 3Y2.65%
5. Dividend
5.1 Amount
XRAY has a Yearly Dividend Yield of 4.91%, which is a nice return.
Compared to an average industry Dividend Yield of 0.20, XRAY pays a better dividend. On top of this XRAY pays more dividend than 99.46% of the companies listed in the same industry.
XRAY's Dividend Yield is rather good when compared to the S&P500 average which is at 1.88.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.91% |
5.2 History
The dividend of XRAY is nicely growing with an annual growth rate of 11.21%!
XRAY has been paying a dividend for at least 10 years, so it has a reliable track record.
XRAY has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)11.21%
Div Incr Years6
Div Non Decr Years30
5.3 Sustainability
The earnings of XRAY are negative and hence is the payout ratio. XRAY will probably not be able to sustain this dividend level.
XRAY's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP-14.4%
EPS Next 2Y-1.68%
EPS Next 3Y2.65%
11.52
+0.3 (+2.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners107.05%
Inst Owner Change9.76%
Ins Owners0.29%
Ins Owner Change-3.01%
Market Cap2.30B
Revenue(TTM)3.62B
Net Income(TTM)-882.00M
Analysts69.52
Price Target12.99 (12.76%)
Short Float %7.14%
Short Ratio3.87
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.91% |
Yearly Dividend0.62
Dividend Growth(5Y)11.21%
DP-14.4%
Div Incr Years6
Div Non Decr Years30
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.77%
Min EPS beat(2)-19.03%
Max EPS beat(2)1.49%
EPS beat(4)2
Avg EPS beat(4)-3.17%
Min EPS beat(4)-40.52%
Max EPS beat(4)45.37%
EPS beat(8)3
Avg EPS beat(8)-1.68%
EPS beat(12)6
Avg EPS beat(12)4.59%
EPS beat(16)7
Avg EPS beat(16)1.99%
Revenue beat(2)0
Avg Revenue beat(2)-1.42%
Min Revenue beat(2)-1.67%
Max Revenue beat(2)-1.16%
Revenue beat(4)1
Avg Revenue beat(4)-1.42%
Min Revenue beat(4)-3.62%
Max Revenue beat(4)0.77%
Revenue beat(8)2
Avg Revenue beat(8)-1.44%
Revenue beat(12)5
Avg Revenue beat(12)-0.9%
Revenue beat(16)5
Avg Revenue beat(16)-2.02%
PT rev (1m)-19.81%
PT rev (3m)-24.18%
EPS NQ rev (1m)-0.64%
EPS NQ rev (3m)-42.56%
EPS NY rev (1m)-14.54%
EPS NY rev (3m)-15.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.3%
Revenue NY rev (1m)-0.27%
Revenue NY rev (3m)-0.32%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.29 | ||
| Fwd PE | 7.14 | ||
| P/S | 0.63 | ||
| P/FCF | 28.74 | ||
| P/OCF | 10.4 | ||
| P/B | 1.56 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.91 |
EPS(TTM)1.58
EY13.72%
EPS(NY)1.61
Fwd EY14.01%
FCF(TTM)0.4
FCFY3.48%
OCF(TTM)1.11
OCFY9.61%
SpS18.16
BVpS7.41
TBVpS-4.29
PEG (NY)N/A
PEG (5Y)N/A
Graham Number16.23
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.6% | ||
| ROE | -59.68% | ||
| ROCE | 6.38% | ||
| ROIC | 5.04% | ||
| ROICexc | 5.51% | ||
| ROICexgc | 13.81% | ||
| OM | 7.48% | ||
| PM (TTM) | N/A | ||
| GM | 51.1% | ||
| FCFM | 2.21% |
ROA(3y)-10.01%
ROA(5y)-5.27%
ROE(3y)-25.27%
ROE(5y)-13.81%
ROIC(3y)4.11%
ROIC(5y)4.26%
ROICexc(3y)4.36%
ROICexc(5y)4.5%
ROICexgc(3y)15.64%
ROICexgc(5y)20.94%
ROCE(3y)5.38%
ROCE(5y)5.49%
ROICexgc growth 3Y-31.16%
ROICexgc growth 5Y-12.42%
ROICexc growth 3Y-13.44%
ROICexc growth 5Y-4.44%
OM growth 3Y-25.8%
OM growth 5Y-12.74%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.16%
GM growth 5Y-0.95%
F-Score4
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.36 | ||
| Debt/FCF | 29.94 | ||
| Debt/EBITDA | 3.26 | ||
| Cap/Depr | 40.63% | ||
| Cap/Sales | 3.89% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 35.76% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.47 | ||
| Quick Ratio | 0.99 | ||
| Altman-Z | 0.92 |
F-Score4
WACC6.19%
ROIC/WACC0.81
Cap/Depr(3y)46.81%
Cap/Depr(5y)41.51%
Cap/Sales(3y)4.1%
Cap/Sales(5y)3.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.59%
EPS 3Y-16.51%
EPS 5Y-7.38%
EPS Q2Q%-26%
EPS Next Y-1.97%
EPS Next 2Y-1.68%
EPS Next 3Y2.65%
EPS Next 5Y7.4%
Revenue 1Y (TTM)-7.08%
Revenue growth 3Y-3.58%
Revenue growth 5Y-1.17%
Sales Q2Q%-4.94%
Revenue Next Year-4.33%
Revenue Next 2Y-1.81%
Revenue Next 3Y-0.41%
Revenue Next 5Y1.34%
EBIT growth 1Y3.04%
EBIT growth 3Y-28.45%
EBIT growth 5Y-13.75%
EBIT Next Year42.44%
EBIT Next 3Y14.44%
EBIT Next 5Y11.96%
FCF growth 1Y-63.3%
FCF growth 3Y-18.29%
FCF growth 5Y-11.45%
OCF growth 1Y-38.44%
OCF growth 3Y-11.14%
OCF growth 5Y-6.32%
DENTSPLY SIRONA INC / XRAY FAQ
Can you provide the ChartMill fundamental rating for DENTSPLY SIRONA INC?
ChartMill assigns a fundamental rating of 4 / 10 to XRAY.
Can you provide the valuation status for DENTSPLY SIRONA INC?
ChartMill assigns a valuation rating of 7 / 10 to DENTSPLY SIRONA INC (XRAY). This can be considered as Undervalued.
How profitable is DENTSPLY SIRONA INC (XRAY) stock?
DENTSPLY SIRONA INC (XRAY) has a profitability rating of 4 / 10.
What is the valuation of DENTSPLY SIRONA INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for DENTSPLY SIRONA INC (XRAY) is 7.29 and the Price/Book (PB) ratio is 1.56.
How sustainable is the dividend of DENTSPLY SIRONA INC (XRAY) stock?
The dividend rating of DENTSPLY SIRONA INC (XRAY) is 7 / 10 and the dividend payout ratio is -14.4%.